Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Sanofi ( (SNY) ) just unveiled an announcement.
In February 2026, Sanofi highlighted new real-world data on its RSV antibody Beyfortus, showing strong performance in a universal infant immunization program in Galicia, Spain. The NIRSE-GAL study, published on February 16, 2026 in The Lancet Infectious Diseases, reported that immunized infants saw an 85.9% reduction in RSV-related lower respiratory tract infection hospitalizations during their first season and 55.3% fewer hospitalizations in their second season.
The study also showed double-digit reductions in primary care visits for bronchitis, bronchiolitis, lower respiratory infections, and wheezing or asthma, as well as marked declines in rehospitalizations among infants previously hospitalized for RSV. Together with more than 50 real-world studies and over 11 million infants immunized globally, these findings reinforce Beyfortus as a key asset in Sanofi’s vaccines portfolio and strengthen its position in the competitive pediatric respiratory prevention market, with implications for healthcare budgets and infant care strategies worldwide.
The most recent analyst rating on (SNY) stock is a Hold with a $57.00 price target. To see the full list of analyst forecasts on Sanofi stock, see the SNY Stock Forecast page.
Spark’s Take on SNY Stock
According to Spark, TipRanks’ AI Analyst, SNY is a Outperform.
The score is driven primarily by solid financial resilience and a constructive earnings outlook (growth, margin expansion, and buybacks). Valuation is supportive with a reasonable P/E and strong dividend, while weaker technical trend signals (below major moving averages and negative MACD) temper the overall rating.
To see Spark’s full report on SNY stock, click here.
More about Sanofi
Sanofi is an R&D-driven, AI-powered biopharmaceutical company that develops medicines and vaccines for immune and other diseases, serving patients worldwide. Listed on Euronext Paris and Nasdaq, it focuses on high-impact therapies and preventative treatments that can reach millions of people through both innovative pipelines and established products.
Average Trading Volume: 3,514,020
Technical Sentiment Signal: Sell
Current Market Cap: $110.7B
For an in-depth examination of SNY stock, go to TipRanks’ Overview page.